文献速递炎症性肠病

乌帕替尼与瑞莎珠单抗在抗TNF经治克罗恩病患者中的真实世界疗效比较

Real-World Outcomes of Upadacitinib vs Risankizumab Among Anti-Tumor Necrosis Factor-Exposed Patients With Crohn's Disease.
PubMed 文献 · Clin Gastroenterol Hepatol · 2026-06-15

这项回顾性单中心队列研究纳入175例抗TNF经治的活动性管腔型克罗恩病患者,比较乌帕替尼(n=60)与瑞莎珠单抗(n=115)的疗效。经逆概率治疗加权及疾病严重度校正后,两组诱导后无激素临床缓解(aOR 1.05,95%CI 0.46-2.41)及联合无激素临床与生化缓解(aOR 1.14,95%CI 0.48-2.72)均无显著差异,治疗持续性和不良事件率亦相似。

要点

  • 抗TNF经治克罗恩病患者中,乌帕替尼与瑞莎珠单抗诱导后无激素临床缓解率相似。
  • 校正基线差异后,联合无激素临床与生化缓解及52周结局均无显著差异。
  • 两组治疗持续性和严重及感染性不良事件率相似。

核心结论

  • 在抗TNF经治的活动性管腔型克罗恩病患者中,乌帕替尼与瑞莎珠单抗经基线差异校正后达到相似的诱导后缓解。

研究设计与样本

  • 回顾性单中心队列研究,纳入2022年1月至2025年11月启动乌帕替尼或瑞莎珠单抗的成人克罗恩病患者。
  • 共175例抗TNF经治患者,其中瑞莎珠单抗115例、乌帕替尼60例。
  • 采用逆概率治疗加权并额外校正基线疾病严重度,敏感性分析包括权重截断和重叠权重。

主要发现

  • 未校正诱导后无激素临床缓解:乌帕替尼组60%(33/55),瑞莎珠单抗组55%(60/109)。
  • 校正后诱导后无激素临床缓解无显著差异(aOR 1.05,95%CI 0.46-2.41)。
  • 校正后联合无激素临床与生化缓解无显著差异(aOR 1.14,95%CI 0.48-2.72)。
  • 第52周缓解估计受随访减少限制,校正后亦无显著差异。
  • 校正后两组治疗持续性和严重及感染性不良事件率相似。

临床怎么用

  • 对于抗TNF经治的活动性管腔型克罗恩病患者,乌帕替尼与瑞莎珠单抗均可作为后续治疗选择,疗效预期相近。

局限性

  • 回顾性单中心设计。
  • 第52周结局受随访减少限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The optimal sequencing of therapy following anti-tumor necrosis factor inhibitor failure in Crohn's disease remains uncertain. We compared the effectiveness of upadacitinib vs risankizumab in patients with active luminal Crohn's disease previously exposed to anti-tumor necrosis factor therapies. METHODS: We conducted a retrospective single-center cohort study of adults with Crohn's disease initiating upadacitinib or risankizumab (January 2022-November 2025). The primary outcome was postinduction (week 12-24) corticosteroid-free clinical remission. Secondary outcomes included corticosteroid-free clinical remission at week 52, combined corticosteroid-free clinical and biochemical remission postinduction and at week 52, biomarker and endoscopic changes, treatment persistence, and adverse events. Inverse probability of treatment weighting with additional adjustment for baseline disease severity was used to account for baseline differences; sensitivity analyses included weight truncation and overlap weighting. RESULTS: Among 175 anti-tumor necrosis factor-exposed patients (risankizumab, n = 115; upadacitinib, n = 60), unadjusted postinduction corticosteroid-free clinical remission occurred in 60% (33/55) of upadacitinib-treated patients and 55% (60/109) of risankizumab-treated patients. After inverse probability of treatment weighting and disease severity adjustment, there was no significant difference in postinduction corticosteroid-free clinical remission (adjusted odds ratio, 1.05; 95% confidence interval, 0.46-2.41) or combined corticosteroid-free clinical and biochemical remission (adjusted odds ratio, 1.14; 95% confidence interval, 0.48-2.72). At week 52, remission estimates were limited by reduced follow-up but were also not significantly different after adjustment. Treatment persistence and serious and infectious adverse event rates were similar between groups after adjustment. CONCLUSIONS: In anti-tumor necrosis factor-exposed patients with active luminal Crohn's disease, upadacitinib and risankizumab achieved similar postinduction remission after adjustment for baseline differences.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. McShane C, Olivera PA, Candido K, et al. Real-World Outcomes of Upadacitinib vs Risankizumab Among Anti-Tumor Necrosis Factor-Exposed Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2026. PMID: 42297318. doi:10.1016/j.cgh.2026.06.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。